Please use this identifier to cite or link to this item:
標題: Antimetastatic Effects and Mechanisms of Apo-8 '-Lycopenal, an Enzymatic Metabolite of Lycopene, Against Human Hepatocarcinoma SK-Hep-1 Cells
作者: Yang, C.M.
Hu, T.Y.
Hu, M.L.
關鍵字: focal adhesion kinase;prostate-cancer cells;sialyl-lewis-x;matrix;metalloproteinases;beta-carotene;hepatocellular-carcinoma;signaling;pathways;pancreatic-cancer;delivery vehicle;apo-lycopenals
Project: Nutrition and Cancer-an International Journal
期刊/報告no:: Nutrition and Cancer-an International Journal, Volume 64, Issue 2, Page(s) 274-285.
Lycopene is primarily metabolized by carotenoid monoxygenase II into apo-8'- and apo-12'-lycopenal in the rat liver. Although lycopene possesses antimetastatic activity in a highly invasive hepatoma SK-Hep-1 cell line, little is known whether its metabolites have a similar effect. In this study, we investigated the antimetastatic effects of apo-8'-lycopenal (1-10 mu M) in comparison with lycopene (10 mu M) in SK-Hep-1 cells. We found that both apo-8'-lycopenal and lycopene inhibited the invasion and migration of SK-Hep-1 cells, and the effect of apo-8'-lycopenal was stronger than that of lycopene at the same concentration (10 mu M). Mechanistically, apo-8'-lycopenal: 1) decreased the activities and protein expression of metalloproteinase-2 (MMP-2) and -9; 2) increased the protein expression of nm23-H1 and the tissue inhibitor of MMP (TIMP)-1 and -2; 3) suppressed protein expression of Rho small GTPases; and 4) inhibited focal adhesion kinase-mediated signaling pathway, such as ERK/p38 and PI3K-Akt axis. Overall, these results demonstrate that apo-8'-lycopenal possesses antimetastatic activity in SK-Hep-1 cells and that this effect is stronger than that of lycopene, suggesting that the antimetastatic effect may be attributed, at least in part, to its metabolites such as apo-8'-lycopenal.
ISSN: 0163-5581
DOI: 10.1080/01635581.2012.643273
Appears in Collections:期刊論文

Show full item record

Google ScholarTM




Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.